In conclusion, these results demonstrate that AKT1 serves as a key target of Hyp, through which Hyp exerts its therapeutic effects in LN by suppressing podocyte PANoptosis and improving renal pathology and function. The gene discussed is AKT1; the disease is lobular neoplasia.